STAT+: Pharmalittle: Biogen ALS drug trial yields mixed signals; Novartis makes U.S. growth its top priority
Hello, everyone, and how are you today? A dank cloudy cover greeted us this morning, but we are ignoring the gloom by keeping busy. After all, there is much to be done. There are deadlines to meet, a variety of reading material to digest, and calls to make. We trust you can relate. So please join us as we fortify ourselves with more cups of stimulation — we are back to blueberry cobbler — and get started. Hope you conquer the world and accomplish much. And of course, be in touch. …
Over the last six years, a venture capital team run by Bayer invested roughly $1.5 billion into small biotech startups and now the unit is ramping up with plans to invest a nearly identical pot of money — this time, $1.3 billion — in half the time, according to STAT. Bayer launched its venture arm, Leaps by Bayer, in 2015. The team scouts out startups that the drugmaker could invest in and potentially make a bit of money. But more importantly, its mandate is to find biotech and agriculture startups that might one day make for interesting R&D partners, or acquisition targets.
Continue to STAT+ to read the full story…
